BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

enGene, Inc. Adds Leading Nanomedicine Expert To Scientific Advisory Board


9/2/2010 9:44:10 AM

VANCOUVER, BRITISH COLUMBIA--(Marketwire - September 01, 2010) - enGene Inc., a privately held biotechnology company developing an innovative platform technology to deliver nucleotides (DNA or siRNA) to mucosal tissue for treating a variety of diseases, including inflammatory bowel disease (IBD) and diabetes, announced today that Dr. Russell J. Mumper has joined the Company's Scientific Advisory Board.

Dr. Mumper is an internationally recognized leader in developing nanotechnologies for drug delivery. He is currently the Executive Associate Dean for Academics and the John A. McNeill Distinguished Professor at the UNC Eshelman School of Pharmacy at the University of North Carolina (UNC) at Chapel Hill. He also serves as the Director of the Center for Nanotechnology in Drug Delivery at UNC. Dr. Mumper has contributed extensively to the fields of nano-scale drug delivery systems, drug-polymer conjugates, and trans-mucosal drug and vaccine delivery. He has received over $14 million in research grants and contracts, authored more than 215 scientific publications/abstracts and holds 38 granted and pending patents. Notably, Dr. Mumper was the first scientist to demonstrate the use of chitosan as a carrier for nucleotides and holds the earliest patent in this field.

"I'm impressed by the in vivo efficacy of the nucleotide delivery system developed by enGene's scientists and the potential of the technology to address critical unmet needs in medicine," says Dr. Mumper.

"We are very pleased to have Dr. Mumper join our Scientific Advisory Board. He brings to enGene a wealth of knowledge and expertise in formulation of nanoparticles for pharmaceutical applications, drug development and large-scale cGMP manufacturing of nanoparticles," says Anthony T. Cheung, enGene's Chief Scientific Officer. "Dr. Mumper's in-depth expertise in trans-mucosal drug delivery and formulation and engineering of nanoparticles will be extremely relevant to enGene's current research direction, as we embark on developing an oral formulation for our nucleotide delivery system. We look forward to his strategic contribution to our research and development programs."

More about enGene

enGene Inc. has developed a highly flexible, biopolymer-based nucleotide (DNA and siRNA) delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels. Our platform technology has the ability to significantly impact diseases of mucosal tissues such as the gastrointestinal tract, lung and bladder as well as provide systemic release of proteins from the gut to treat diabetes, anemia, hemophilia and others. The two lead programs are the localized delivery of an anti-inflammatory cytokine, IL-10, for treating Inflammatory Bowel Disease and delivery of insulin in a physiologic, meal-dependent fashion to regulate blood glucose levels. For more information please visit www.engeneinc.com.


Contacts:
enGene Inc.
Eric A. Adams
CEO
604.221.4362
604.221.4369 (FAX)
info@engeneinc.com
www.engeneinc.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES